Abstract:
The novel phthalimide derivatives were designed and synthesized by
modifying of the phthalimide structures based on the three-dimentional quantitative
structure-activity relationship (3D QSAR), comparative molecular field analysis
(CoMFA) and comparative molecular similarity indices analysis (CoMSIA) studies.
These derivatives were synthesized using phthalimide and substituted benzyl halide in
the presence potassium hydroxide. Six newly synthesized compounds were evaluated
for HIV-1 reverse transcriptase inhibitory activity by radioactivity assay at
concentration 200 μg/mL using poly(rA).oligo(dT) as template-primer, methyl-
[3H]dTTP as substrate and doxorubicin (1.25 mM) as positive control. The
synthesized compounds showed low inhibitory activity in the range of 7.9-22.9 %
inhibition. Since infection with HIV-1 is associated with an increase risk of
developing certain types of cancer, the previously and newly synthesized phthalimide
derivatives have been subjected to cytotoxic activity testing using MTT colorimetric
method against the cancer cell lines KB and HeLa and normal vero cell line. 1-
Phthalimidomethyl-4-tert-butylbenzene, compound 36 demonstrated promising
cytotoxic activity that was less toxic to normal cells.